| Category | Name | IntersectionWithQuery | PValue | GenesInTerm | GenesInQuery | GenesInTermInQuery | ID |
|---|---|---|---|---|---|---|---|
| GeneOntologyMolecularFunction | kainate selective glutamate receptor activity | 5.95e-07 | 6 | 63 | 3 | GO:0015277 | |
| GeneOntologyMolecularFunction | ligand-gated calcium channel activity | 2.66e-06 | 31 | 63 | 4 | GO:0099604 | |
| GeneOntologyMolecularFunction | ligand-gated monoatomic cation channel activity | 5.22e-06 | 140 | 63 | 6 | GO:0099094 | |
| GeneOntologyMolecularFunction | glutamate-gated receptor activity | 1.97e-05 | 17 | 63 | 3 | GO:0004970 | |
| GeneOntologyMolecularFunction | ligand-gated sodium channel activity | 2.36e-05 | 18 | 63 | 3 | GO:0015280 | |
| GeneOntologyMolecularFunction | intracellularly gated calcium channel activity | 2.36e-05 | 18 | 63 | 3 | GO:0015278 | |
| GeneOntologyMolecularFunction | ligand-gated monoatomic ion channel activity | 3.24e-05 | 193 | 63 | 6 | GO:0015276 | |
| GeneOntologyMolecularFunction | ligand-gated channel activity | 3.64e-05 | 197 | 63 | 6 | GO:0022834 | |
| GeneOntologyMolecularFunction | ligand-gated monoatomic ion channel activity involved in regulation of presynaptic membrane potential | 5.78e-05 | 24 | 63 | 3 | GO:0099507 | |
| GeneOntologyMolecularFunction | ryanodine-sensitive calcium-release channel activity | 5.85e-05 | 4 | 63 | 2 | GO:0005219 | |
| GeneOntologyMolecularFunction | glutamate receptor activity | 8.29e-05 | 27 | 63 | 3 | GO:0008066 | |
| GeneOntologyMolecularFunction | calcium-induced calcium release activity | 1.46e-04 | 6 | 63 | 2 | GO:0048763 | |
| GeneOntologyMolecularFunction | intracellularly ligand-gated monoatomic ion channel activity | 1.53e-04 | 33 | 63 | 3 | GO:0005217 | |
| GeneOntologyMolecularFunction | extracellularly glutamate-gated ion channel activity | 2.04e-04 | 7 | 63 | 2 | GO:0005234 | |
| GeneOntologyMolecularFunction | scaffold protein binding | 2.13e-04 | 93 | 63 | 4 | GO:0097110 | |
| GeneOntologyMolecularFunction | monoatomic ion channel activity | 5.90e-04 | 459 | 63 | 7 | GO:0005216 | |
| GeneOntologyMolecularFunction | sodium channel activity | 5.92e-04 | 52 | 63 | 3 | GO:0005272 | |
| GeneOntologyMolecularFunction | metal ion transmembrane transporter activity | 6.37e-04 | 465 | 63 | 7 | GO:0046873 | |
| GeneOntologyMolecularFunction | gated channel activity | 6.38e-04 | 334 | 63 | 6 | GO:0022836 | |
| GeneOntologyMolecularFunction | monoatomic cation channel activity | 7.33e-04 | 343 | 63 | 6 | GO:0005261 | |
| GeneOntologyMolecularFunction | calcium channel activity | 7.37e-04 | 129 | 63 | 4 | GO:0005262 | |
| GeneOntologyMolecularFunction | transmitter-gated monoatomic ion channel activity involved in regulation of postsynaptic membrane potential | 7.76e-04 | 57 | 63 | 3 | GO:1904315 | |
| GeneOntologyMolecularFunction | SNARE binding | 8.98e-04 | 136 | 63 | 4 | GO:0000149 | |
| GeneOntologyMolecularFunction | neurotransmitter receptor activity involved in regulation of postsynaptic membrane potential | 9.01e-04 | 60 | 63 | 3 | GO:0099529 | |
| GeneOntologyMolecularFunction | transmitter-gated channel activity | 1.14e-03 | 65 | 63 | 3 | GO:0022835 | |
| GeneOntologyMolecularFunction | transmitter-gated monoatomic ion channel activity | 1.14e-03 | 65 | 63 | 3 | GO:0022824 | |
| GeneOntologyMolecularFunction | channel activity | 1.29e-03 | 525 | 63 | 7 | GO:0015267 | |
| GeneOntologyMolecularFunction | passive transmembrane transporter activity | 1.31e-03 | 526 | 63 | 7 | GO:0022803 | |
| GeneOntologyMolecularFunction | calcium ion transmembrane transporter activity | 1.32e-03 | 151 | 63 | 4 | GO:0015085 | |
| GeneOntologyMolecularFunction | postsynaptic neurotransmitter receptor activity | 1.72e-03 | 75 | 63 | 3 | GO:0098960 | |
| GeneOntologyMolecularFunction | extracellular ligand-gated monoatomic ion channel activity | 1.85e-03 | 77 | 63 | 3 | GO:0005230 | |
| GeneOntologyMolecularFunction | protein serine/threonine kinase binding | 2.59e-03 | 24 | 63 | 2 | GO:0120283 | |
| GeneOntologyMolecularFunction | monoatomic ion transmembrane transporter activity | 3.35e-03 | 793 | 63 | 8 | GO:0015075 | |
| GeneOntologyMolecularFunction | inorganic cation transmembrane transporter activity | 3.51e-03 | 627 | 63 | 7 | GO:0022890 | |
| GeneOntologyMolecularFunction | neurotransmitter receptor activity | 3.89e-03 | 100 | 63 | 3 | GO:0030594 | |
| GeneOntologyMolecularFunction | amino acid transmembrane transporter activity | 4.46e-03 | 105 | 63 | 3 | GO:0015171 | |
| GeneOntologyMolecularFunction | monoatomic cation transmembrane transporter activity | 4.80e-03 | 664 | 63 | 7 | GO:0008324 | |
| GeneOntologyMolecularFunction | low-density lipoprotein particle receptor binding | 5.15e-03 | 34 | 63 | 2 | GO:0050750 | |
| GeneOntologyMolecularFunction | calmodulin binding | 6.01e-03 | 230 | 63 | 4 | GO:0005516 | |
| GeneOntologyMolecularFunction | lipoprotein particle receptor binding | 6.73e-03 | 39 | 63 | 2 | GO:0070325 | |
| GeneOntologyBiologicalProcess | negative regulation of synaptic transmission, glutamatergic | 7.24e-06 | 13 | 62 | 3 | GO:0051967 | |
| GeneOntologyBiologicalProcess | ionotropic glutamate receptor signaling pathway | 7.19e-05 | 27 | 62 | 3 | GO:0035235 | |
| GeneOntologyBiologicalProcess | inhibitory postsynaptic potential | 7.19e-05 | 27 | 62 | 3 | GO:0060080 | |
| GeneOntologyCellularComponent | kainate selective glutamate receptor complex | 5.18e-07 | 6 | 63 | 3 | GO:0032983 | |
| GeneOntologyCellularComponent | sodium channel complex | 9.01e-05 | 29 | 63 | 3 | GO:0034706 | |
| GeneOntologyCellularComponent | ionotropic glutamate receptor complex | 3.38e-04 | 45 | 63 | 3 | GO:0008328 | |
| GeneOntologyCellularComponent | neurotransmitter receptor complex | 4.62e-04 | 50 | 63 | 3 | GO:0098878 | |
| GeneOntologyCellularComponent | cation channel complex | 7.11e-04 | 235 | 63 | 5 | GO:0034703 | |
| GeneOntologyCellularComponent | Cul4A-RING E3 ubiquitin ligase complex | 7.95e-04 | 14 | 63 | 2 | GO:0031464 | |
| GeneOntologyCellularComponent | monoatomic ion channel complex | 9.58e-04 | 378 | 63 | 6 | GO:0034702 | |
| Domain | RIH_assoc | 6.58e-07 | 6 | 61 | 3 | PF08454 | |
| Domain | RIH_assoc-dom | 6.58e-07 | 6 | 61 | 3 | IPR013662 | |
| Domain | RIH_dom | 6.58e-07 | 6 | 61 | 3 | IPR000699 | |
| Domain | Ins145_P3_rcpt | 6.58e-07 | 6 | 61 | 3 | IPR014821 | |
| Domain | Ryanodine_recept-rel | 6.58e-07 | 6 | 61 | 3 | IPR015925 | |
| Domain | - | 6.58e-07 | 6 | 61 | 3 | 1.25.10.30 | |
| Domain | RYDR_ITPR | 6.58e-07 | 6 | 61 | 3 | PF01365 | |
| Domain | Ins145_P3_rec | 6.58e-07 | 6 | 61 | 3 | PF08709 | |
| Domain | MIR | 3.91e-06 | 10 | 61 | 3 | PS50919 | |
| Domain | MIR | 3.91e-06 | 10 | 61 | 3 | PF02815 | |
| Domain | MIR | 3.91e-06 | 10 | 61 | 3 | SM00472 | |
| Domain | MIR_motif | 3.91e-06 | 10 | 61 | 3 | IPR016093 | |
| Domain | Iontro_rcpt | 2.61e-05 | 18 | 61 | 3 | IPR001320 | |
| Domain | Lig_chan-Glu_bd | 2.61e-05 | 18 | 61 | 3 | PF10613 | |
| Domain | Iono_rcpt_met | 2.61e-05 | 18 | 61 | 3 | IPR001508 | |
| Domain | Glu/Gly-bd | 2.61e-05 | 18 | 61 | 3 | IPR019594 | |
| Domain | Lig_chan-Glu_bd | 2.61e-05 | 18 | 61 | 3 | SM00918 | |
| Domain | Lig_chan | 2.61e-05 | 18 | 61 | 3 | PF00060 | |
| Domain | PBPe | 2.61e-05 | 18 | 61 | 3 | SM00079 | |
| Domain | Ryanrecept_TM4-6 | 3.14e-05 | 3 | 61 | 2 | IPR009460 | |
| Domain | Taxilin_fam | 3.14e-05 | 3 | 61 | 2 | IPR026183 | |
| Domain | RyR | 3.14e-05 | 3 | 61 | 2 | PF02026 | |
| Domain | Ryanodine_rcpt | 3.14e-05 | 3 | 61 | 2 | IPR003032 | |
| Domain | RR_TM4-6 | 3.14e-05 | 3 | 61 | 2 | PF06459 | |
| Domain | Ryan_recept | 3.14e-05 | 3 | 61 | 2 | IPR013333 | |
| Domain | Taxilin | 6.27e-05 | 4 | 61 | 2 | PF09728 | |
| Domain | Cullin_CS | 2.18e-04 | 7 | 61 | 2 | IPR016157 | |
| Domain | CULLIN | 2.18e-04 | 7 | 61 | 2 | SM00182 | |
| Domain | ANF_lig-bd_rcpt | 2.38e-04 | 37 | 61 | 3 | IPR001828 | |
| Domain | ANF_receptor | 2.38e-04 | 37 | 61 | 3 | PF01094 | |
| Domain | Peripla_BP_I | 2.79e-04 | 39 | 61 | 3 | IPR028082 | |
| Domain | Cullin_Nedd8 | 2.90e-04 | 8 | 61 | 2 | PF10557 | |
| Domain | Cullin_Nedd8 | 2.90e-04 | 8 | 61 | 2 | SM00884 | |
| Domain | Cullin_neddylation_domain | 2.90e-04 | 8 | 61 | 2 | IPR019559 | |
| Domain | Cullin_homology | 3.72e-04 | 9 | 61 | 2 | IPR016158 | |
| Domain | Lipase/vitellogenin | 4.64e-04 | 10 | 61 | 2 | IPR013818 | |
| Domain | TAG_lipase | 4.64e-04 | 10 | 61 | 2 | IPR000734 | |
| Domain | Cullin | 4.64e-04 | 10 | 61 | 2 | PF00888 | |
| Domain | CULLIN_2 | 4.64e-04 | 10 | 61 | 2 | PS50069 | |
| Domain | Lipase_LIPH | 4.64e-04 | 10 | 61 | 2 | IPR016272 | |
| Domain | Lipase | 4.64e-04 | 10 | 61 | 2 | PF00151 | |
| Domain | Lipase_N | 4.64e-04 | 10 | 61 | 2 | IPR033906 | |
| Domain | Cullin_N | 4.64e-04 | 10 | 61 | 2 | IPR001373 | |
| Domain | CULLIN_1 | 4.64e-04 | 10 | 61 | 2 | PS01256 | |
| Domain | Cullin_repeat-like_dom | 6.78e-04 | 12 | 61 | 2 | IPR016159 | |
| Domain | ARM-type_fold | 8.20e-04 | 339 | 61 | 6 | IPR016024 | |
| Domain | EF-hand_1 | 1.54e-03 | 152 | 61 | 4 | PF00036 | |
| Domain | Spectrin | 2.54e-03 | 23 | 61 | 2 | PF00435 | |
| Domain | LIPASE_SER | 3.24e-03 | 26 | 61 | 2 | PS00120 | |
| Domain | Spectrin_repeat | 4.02e-03 | 29 | 61 | 2 | IPR002017 | |
| Domain | Spectrin/alpha-actinin | 4.89e-03 | 32 | 61 | 2 | IPR018159 | |
| Domain | SPEC | 4.89e-03 | 32 | 61 | 2 | SM00150 | |
| Domain | Ion_trans_dom | 6.16e-03 | 114 | 61 | 3 | IPR005821 | |
| Domain | Ion_trans | 6.16e-03 | 114 | 61 | 3 | PF00520 | |
| Pathway | REACTOME_IONOTROPIC_ACTIVITY_OF_KAINATE_RECEPTORS | 4.95e-06 | 10 | 50 | 3 | M10272 | |
| Pathway | KEGG_MEDICUS_PATHOGEN_HIV_VPR_TO_CDC25_CELL_CYCLE_G2M | 6.79e-06 | 11 | 50 | 3 | M47573 | |
| Pathway | WP_VALPROIC_ACID_PATHWAY | 9.03e-06 | 12 | 50 | 3 | M39371 | |
| Pathway | REACTOME_IONOTROPIC_ACTIVITY_OF_KAINATE_RECEPTORS | 9.03e-06 | 12 | 50 | 3 | MM15142 | |
| Pathway | KEGG_MEDICUS_VARIANT_SCRAPIE_CONFORMATION_PRPSC_TO_MGLUR5_CA2_APOPTOTIC_PATHWAY | 3.91e-05 | 19 | 50 | 3 | M47760 | |
| Pathway | REACTOME_ACTIVATION_OF_KAINATE_RECEPTORS_UPON_GLUTAMATE_BINDING | 1.59e-04 | 30 | 50 | 3 | M18193 | |
| Pathway | REACTOME_ACTIVATION_OF_KAINATE_RECEPTORS_UPON_GLUTAMATE_BINDING | 1.94e-04 | 32 | 50 | 3 | MM15143 | |
| Pathway | REACTOME_DNA_DAMAGE_RECOGNITION_IN_GG_NER | 3.25e-04 | 38 | 50 | 3 | M27592 | |
| Pathway | REACTOME_DNA_DAMAGE_RECOGNITION_IN_GG_NER | 3.25e-04 | 38 | 50 | 3 | MM15301 | |
| Pathway | REACTOME_FORMATION_OF_INCISION_COMPLEX_IN_GG_NER | 4.69e-04 | 43 | 50 | 3 | M1005 | |
| Pathway | KEGG_NUCLEOTIDE_EXCISION_REPAIR | 5.02e-04 | 44 | 50 | 3 | M18937 | |
| Pathway | WP_NUCLEOTIDE_EXCISION_REPAIR | 5.02e-04 | 44 | 50 | 3 | M39847 | |
| Pathway | KEGG_VALINE_LEUCINE_AND_ISOLEUCINE_DEGRADATION | 5.02e-04 | 44 | 50 | 3 | M11835 | |
| Pathway | REACTOME_FORMATION_OF_INCISION_COMPLEX_IN_GG_NER | 5.36e-04 | 45 | 50 | 3 | MM15302 | |
| Pathway | KEGG_MEDICUS_REFERENCE_ISOLEUCINE_DEGRADATION | 5.45e-04 | 10 | 50 | 2 | M47635 | |
| Pathway | KEGG_MEDICUS_REFERENCE_BETA_OXIDATION | 6.64e-04 | 11 | 50 | 2 | M47630 | |
| Pathway | KEGG_MEDICUS_REFERENCE_CA2_CAM_VGCC_RYR_SIGNALING_PATHWAY | 6.64e-04 | 11 | 50 | 2 | M47958 | |
| Pathway | WP_DNA_REPAIR_PATHWAYS_FULL_NETWORK | 8.50e-04 | 120 | 50 | 4 | M40049 | |
| Pathway | REACTOME_ION_HOMEOSTASIS | 9.17e-04 | 54 | 50 | 3 | M27460 | |
| Pathway | REACTOME_ION_HOMEOSTASIS | 9.17e-04 | 54 | 50 | 3 | MM15202 | |
| Pathway | WP_CELLTYPE_DEPENDENT_SELECTIVITY_OF_CCK2R_SIGNALING | 9.38e-04 | 13 | 50 | 2 | M39589 | |
| Pathway | WP_MFAP5MEDIATED_OVARIAN_CANCER_CELL_MOTILITY_AND_INVASIVENESS | 9.38e-04 | 13 | 50 | 2 | M39463 | |
| Pathway | BIOCARTA_BCELLSURVIVAL_PATHWAY | 1.26e-03 | 15 | 50 | 2 | M4835 | |
| Pubmed | Kainate receptor-mediated responses in the CA1 field of wild-type and GluR6-deficient mice. | 5.66e-09 | 3 | 63 | 3 | 9880586 | |
| Pubmed | 5.66e-09 | 3 | 63 | 3 | 31513786 | ||
| Pubmed | Differential trafficking of GluR7 kainate receptor subunit splice variants. | 5.66e-09 | 3 | 63 | 3 | 15805114 | |
| Pubmed | 2.26e-08 | 4 | 63 | 3 | 15513934 | ||
| Pubmed | Reduced synaptic function of Kainate receptors in the insular cortex of Fmr1 Knock-out mice. | 2.26e-08 | 4 | 63 | 3 | 30241548 | |
| Pubmed | 2.26e-08 | 4 | 63 | 3 | 19369569 | ||
| Pubmed | Developmental expression patterns of kainate receptors in the mouse spinal cord. | 5.65e-08 | 5 | 63 | 3 | 23076118 | |
| Pubmed | 5.65e-08 | 5 | 63 | 3 | 28228252 | ||
| Pubmed | Development of laminar distributions of kainate receptors in the somatosensory cortex of mice. | 5.65e-08 | 5 | 63 | 3 | 9593973 | |
| Pubmed | Kainate receptors: pharmacology, function and therapeutic potential. | 5.65e-08 | 5 | 63 | 3 | 18793656 | |
| Pubmed | 5.65e-08 | 5 | 63 | 3 | 12223554 | ||
| Pubmed | 5.65e-08 | 5 | 63 | 3 | 18358623 | ||
| Pubmed | Preferential assembly of heteromeric kainate and AMPA receptor amino terminal domains. | 5.65e-08 | 5 | 63 | 3 | 29058671 | |
| Pubmed | 8.43e-08 | 23 | 63 | 4 | 8464923 | ||
| Pubmed | 1.13e-07 | 6 | 63 | 3 | 23463619 | ||
| Pubmed | 1.13e-07 | 6 | 63 | 3 | 20519450 | ||
| Pubmed | Essential Roles of Intracellular Calcium Release Channels in Muscle, Brain, Metabolism, and Aging. | 1.13e-07 | 6 | 63 | 3 | 25966694 | |
| Pubmed | N-glycan content modulates kainate receptor functional properties. | 1.13e-07 | 6 | 63 | 3 | 28714086 | |
| Pubmed | IP3Rs are sufficient for dendritic cell Ca2+ signaling in the absence of RyR1. | 1.13e-07 | 6 | 63 | 3 | 16844763 | |
| Pubmed | 1.97e-07 | 7 | 63 | 3 | 17428973 | ||
| Pubmed | Glutamate receptors in cortical plasticity: molecular and cellular biology. | 1.97e-07 | 7 | 63 | 3 | 9016303 | |
| Pubmed | 1.97e-07 | 7 | 63 | 3 | 19342380 | ||
| Pubmed | Glutamate receptors: brain function and signal transduction. | 1.97e-07 | 7 | 63 | 3 | 9651535 | |
| Pubmed | 1.97e-07 | 7 | 63 | 3 | 11860456 | ||
| Pubmed | 1.97e-07 | 7 | 63 | 3 | 1310861 | ||
| Pubmed | Roles of IP3R and RyR Ca2+ channels in endoplasmic reticulum stress and beta-cell death. | 3.15e-07 | 8 | 63 | 3 | 19033399 | |
| Pubmed | Transmembrane topology of the glutamate receptor subunit GluR6. | 3.15e-07 | 8 | 63 | 3 | 8163463 | |
| Pubmed | Expression of glutamate receptor subunit genes during development of the mouse retina. | 4.72e-07 | 9 | 63 | 3 | 9051806 | |
| Pubmed | KEAP1 Mutations Drive Tumorigenesis by Suppressing SOX9 Ubiquitination and Degradation. | 1.23e-06 | 12 | 63 | 3 | 33173725 | |
| Pubmed | Glutamatergic gene variants impact the clinical profile of efficacy and side effects of haloperidol. | 1.60e-06 | 13 | 63 | 3 | 20859245 | |
| Pubmed | 3.23e-06 | 2 | 63 | 2 | 12947409 | ||
| Pubmed | 3.23e-06 | 2 | 63 | 2 | 15673679 | ||
| Pubmed | 3.23e-06 | 2 | 63 | 2 | 19320626 | ||
| Pubmed | 3.23e-06 | 2 | 63 | 2 | 11182092 | ||
| Pubmed | Kainate receptor-mediated synaptic transmission in the adult anterior cingulate cortex. | 3.23e-06 | 2 | 63 | 2 | 15928066 | |
| Pubmed | Altered ryanodine receptor expression in mild cognitive impairment and Alzheimer's disease. | 3.23e-06 | 2 | 63 | 2 | 21531043 | |
| Pubmed | 3.23e-06 | 2 | 63 | 2 | 16678258 | ||
| Pubmed | 3.23e-06 | 2 | 63 | 2 | 14724198 | ||
| Pubmed | 3.23e-06 | 2 | 63 | 2 | 17620617 | ||
| Pubmed | Q/R site editing in kainate receptor GluR5 and GluR6 pre-mRNAs requires distant intronic sequences. | 3.23e-06 | 2 | 63 | 2 | 8700852 | |
| Pubmed | 3.23e-06 | 2 | 63 | 2 | 15539395 | ||
| Pubmed | 3.23e-06 | 2 | 63 | 2 | 20064923 | ||
| Pubmed | Dysregulation of CUL4A and CUL4B Ubiquitin Ligases in Lung Cancer. | 3.23e-06 | 2 | 63 | 2 | 27974468 | |
| Pubmed | 3.23e-06 | 2 | 63 | 2 | 7696618 | ||
| Pubmed | Atypical functional properties of GluK3-containing kainate receptors. | 3.23e-06 | 2 | 63 | 2 | 20007474 | |
| Pubmed | Q/R site editing controls kainate receptor inhibition by membrane fatty acids. | 3.23e-06 | 2 | 63 | 2 | 16221857 | |
| Pubmed | 3.23e-06 | 2 | 63 | 2 | 16219388 | ||
| Pubmed | Expression and novel subunit isoforms of glutamate receptor genes GluR5 and GluR6. | 3.23e-06 | 2 | 63 | 2 | 8260617 | |
| Pubmed | 3.23e-06 | 2 | 63 | 2 | 24285081 | ||
| Pubmed | Subunit composition and alternative splicing regulate membrane delivery of kainate receptors. | 3.23e-06 | 2 | 63 | 2 | 15014126 | |
| Pubmed | 3.23e-06 | 2 | 63 | 2 | 8898078 | ||
| Pubmed | Assessing the role of GLUK5 and GLUK6 at hippocampal mossy fiber synapses. | 3.23e-06 | 2 | 63 | 2 | 15537878 | |
| Pubmed | Subunit composition of kainate receptors in hippocampal interneurons. | 3.23e-06 | 2 | 63 | 2 | 11144357 | |
| Pubmed | 3.23e-06 | 2 | 63 | 2 | 18586264 | ||
| Pubmed | 3.23e-06 | 2 | 63 | 2 | 25043179 | ||
| Pubmed | 3.23e-06 | 2 | 63 | 2 | 15094479 | ||
| Pubmed | 3.23e-06 | 2 | 63 | 2 | 14550562 | ||
| Pubmed | 3.23e-06 | 2 | 63 | 2 | 15358807 | ||
| Pubmed | Role of GluK1 kainate receptors in seizures, epileptic discharges, and epileptogenesis. | 3.23e-06 | 2 | 63 | 2 | 24760837 | |
| Pubmed | A mosaic of functional kainate receptors in hippocampal interneurons. | 3.23e-06 | 2 | 63 | 2 | 15483117 | |
| Pubmed | Functional characterization of kainate receptors in the mouse nucleus accumbens. | 3.23e-06 | 2 | 63 | 2 | 11985817 | |
| Pubmed | 3.23e-06 | 2 | 63 | 2 | 14985349 | ||
| Pubmed | 3.23e-06 | 2 | 63 | 2 | 11069933 | ||
| Pubmed | 9.68e-06 | 3 | 63 | 2 | 18403125 | ||
| Pubmed | 9.68e-06 | 3 | 63 | 2 | 15509753 | ||
| Pubmed | 9.68e-06 | 3 | 63 | 2 | 18434746 | ||
| Pubmed | 9.68e-06 | 3 | 63 | 2 | 34119472 | ||
| Pubmed | Control of Neuronal Ryanodine Receptor-Mediated Calcium Signaling by Calsenilin. | 9.68e-06 | 3 | 63 | 2 | 29730765 | |
| Pubmed | SPRY domains in ryanodine receptors (Ca(2+)-release channels). | 9.68e-06 | 3 | 63 | 2 | 9204703 | |
| Pubmed | Distinct Subunit Domains Govern Synaptic Stability and Specificity of the Kainate Receptor. | 9.68e-06 | 3 | 63 | 2 | 27346345 | |
| Pubmed | 9.68e-06 | 3 | 63 | 2 | 1379666 | ||
| Pubmed | 9.68e-06 | 3 | 63 | 2 | 7876312 | ||
| Pubmed | 9.68e-06 | 3 | 63 | 2 | 8730589 | ||
| Pubmed | 9.68e-06 | 3 | 63 | 2 | 21881589 | ||
| Pubmed | Isoform-dependent formation of heteromeric Ca2+ release channels (ryanodine receptors). | 9.68e-06 | 3 | 63 | 2 | 12213830 | |
| Pubmed | 9.68e-06 | 3 | 63 | 2 | 32587774 | ||
| Pubmed | 9.68e-06 | 3 | 63 | 2 | 9242641 | ||
| Pubmed | 9.68e-06 | 3 | 63 | 2 | 22948152 | ||
| Pubmed | Cullin4B/E3-ubiquitin ligase negatively regulates beta-catenin. | 9.68e-06 | 3 | 63 | 2 | 17954973 | |
| Pubmed | Developmental changes in expression of the three ryanodine receptor mRNAs in the mouse brain. | 9.68e-06 | 3 | 63 | 2 | 10788707 | |
| Pubmed | RYR2 proteins contribute to the formation of Ca(2+) sparks in smooth muscle. | 9.68e-06 | 3 | 63 | 2 | 15024040 | |
| Pubmed | 9.68e-06 | 3 | 63 | 2 | 32567721 | ||
| Pubmed | 9.68e-06 | 3 | 63 | 2 | 7538211 | ||
| Pubmed | 9.68e-06 | 3 | 63 | 2 | 25239916 | ||
| Pubmed | Ca(2+)-induced Ca2+ release in myocytes from dyspedic mice lacking the type-1 ryanodine receptor. | 9.68e-06 | 3 | 63 | 2 | 7621815 | |
| Pubmed | 9.68e-06 | 3 | 63 | 2 | 18643873 | ||
| Pubmed | 9.68e-06 | 3 | 63 | 2 | 11159936 | ||
| Pubmed | E3 ubiquitin ligase Cullin4B mediated polyubiquitination of p53 for its degradation. | 9.68e-06 | 3 | 63 | 2 | 24452595 | |
| Pubmed | Molecular identification of the ryanodine receptor pore-forming segment. | 9.68e-06 | 3 | 63 | 2 | 10473538 | |
| Pubmed | RNA editing of the glutamate receptor subunits GluR2 and GluR6 in human brain tissue. | 9.68e-06 | 3 | 63 | 2 | 7523595 | |
| Pubmed | 9.68e-06 | 3 | 63 | 2 | 7959768 | ||
| Pubmed | The organization of proteins in the human red blood cell membrane. A review. | 9.68e-06 | 3 | 63 | 2 | 4600883 | |
| Pubmed | 9.68e-06 | 3 | 63 | 2 | 7635066 | ||
| Pubmed | Glutamate can act as a signaling molecule in mouse preimplantation embryos†. | 1.12e-05 | 24 | 63 | 3 | 35746896 | |
| Pubmed | TXLNA ACADSB HSDL2 SYNE1 SPTAN1 UGGT1 RRP12 CLTC HADHA DZIP1 YME1L1 ITPR3 | 1.26e-05 | 1487 | 63 | 12 | 33957083 | |
| Pubmed | A High-Density Human Mitochondrial Proximity Interaction Network. | STRN3 ACADSB HSDL2 SYNE1 KIAA1217 RRP12 CLTC LRP2 XIAP HADHA YME1L1 ITPR3 | 1.34e-05 | 1496 | 63 | 12 | 32877691 |
| Pubmed | LncRNAs-directed PTEN enzymatic switch governs epithelial-mesenchymal transition. | 1.39e-05 | 168 | 63 | 5 | 30631154 | |
| Pubmed | 1.93e-05 | 4 | 63 | 2 | 22100703 | ||
| Pubmed | 1.93e-05 | 4 | 63 | 2 | 17650106 | ||
| Pubmed | 1.93e-05 | 4 | 63 | 2 | 26277340 | ||
| Interaction | GRIK4 interactions | 1.46e-06 | 8 | 61 | 3 | int:GRIK4 | |
| Interaction | GRIK3 interactions | 3.12e-06 | 10 | 61 | 3 | int:GRIK3 | |
| Interaction | DCAF12L2 interactions | 9.38e-06 | 14 | 61 | 3 | int:DCAF12L2 | |
| Interaction | CEP63 interactions | 1.67e-05 | 179 | 61 | 6 | int:CEP63 | |
| Interaction | PTEN interactions | CUL4B CUL4A FSIP2 HSDL2 TOPAZ1 SPTAN1 UGGT1 XIAP HADHA YME1L1 RYR3 ITPR3 | 1.85e-05 | 929 | 61 | 12 | int:PTEN |
| Interaction | GRIK5 interactions | 2.90e-05 | 20 | 61 | 3 | int:GRIK5 | |
| Interaction | COMMD1 interactions | 3.53e-05 | 123 | 61 | 5 | int:COMMD1 | |
| Interaction | ATG16L1 interactions | CWF19L2 TXLNA TXLNB APPL2 KIAA1217 RRP12 CLTC AKAP10 TEX9 YME1L1 RYR2 CENPQ ITPR3 | 3.55e-05 | 1161 | 61 | 13 | int:ATG16L1 |
| Interaction | SIKE1 interactions | 4.48e-05 | 65 | 61 | 4 | int:SIKE1 | |
| Interaction | RYR3 interactions | 5.10e-05 | 24 | 61 | 3 | int:RYR3 | |
| Interaction | CCDC112 interactions | 9.12e-05 | 29 | 61 | 3 | int:CCDC112 | |
| Interaction | USP19 interactions | 1.03e-04 | 154 | 61 | 5 | int:USP19 | |
| Interaction | CFAP53 interactions | 1.12e-04 | 31 | 61 | 3 | int:CFAP53 | |
| Interaction | GRIK2 interactions | 1.23e-04 | 32 | 61 | 3 | int:GRIK2 | |
| Interaction | FBF1 interactions | 1.68e-04 | 171 | 61 | 5 | int:FBF1 | |
| Interaction | GRIK1 interactions | 1.75e-04 | 36 | 61 | 3 | int:GRIK1 | |
| GeneFamily | Glutamate ionotropic receptor kainate type subunits | 1.16e-07 | 5 | 42 | 3 | 1199 | |
| GeneFamily | Ryanodine receptors|Protein phosphatase 1 regulatory subunits | 1.58e-05 | 3 | 42 | 2 | 287 | |
| GeneFamily | Cullins | 1.46e-04 | 8 | 42 | 2 | 1032 | |
| GeneFamily | WD repeat domain containing|Protein phosphatase 2 regulatory subunits | 5.43e-04 | 15 | 42 | 2 | 696 | |
| GeneFamily | Lipases|Arylacetamide deacetylase family | 1.18e-03 | 22 | 42 | 2 | 464 | |
| GeneFamily | EF-hand domain containing | 1.63e-03 | 219 | 42 | 4 | 863 | |
| Coexpression | GSE14000_UNSTIM_VS_16H_LPS_DC_TRANSLATED_RNA_UP | 7.95e-06 | 197 | 63 | 6 | M3343 | |
| Coexpression | GSE12392_WT_VS_IFNB_KO_CD8A_NEG_SPLEEN_DC_DN | 8.66e-06 | 200 | 63 | 6 | M7150 | |
| ToppCell | facs-Thymus-Thymus_Epithelium-18m-Lymphocytic|Thymus / Spleen_Marrow_Thymus - method, tissue, subtissue, age, lineage, cell ontology and free annotation | 2.41e-07 | 184 | 63 | 6 | ea7a7e2bac46d4d2c31a5d576b38a032b5335062 | |
| ToppCell | facs-Thymus-Thymus_Epithelium-18m-Lymphocytic-thymocyte|Thymus / Spleen_Marrow_Thymus - method, tissue, subtissue, age, lineage, cell ontology and free annotation | 2.41e-07 | 184 | 63 | 6 | 2cbed6462fea2622871bb7e49b0df3d984239281 | |
| ToppCell | facs-Thymus-Thymus_Epithelium-18m-Lymphocytic-proliferating_thymocyte;_DN_to_DP_transition,_dividing_(some_are_Cd8+/_Cd4+,_some_undergoing_VDJ_recombination)|Thymus / Spleen_Marrow_Thymus - method, tissue, subtissue, age, lineage, cell ontology and free annotation | 2.41e-07 | 184 | 63 | 6 | 2b19a8c5f823e00812908b23e66bb4e563278aff | |
| ToppCell | COVID-19-Heart-Neuronal|Heart / Disease (COVID-19 only), tissue and cell type | 4.65e-06 | 173 | 63 | 5 | 6fb5f9e6536a5d57fd8e6657b494047a2d0bc9c7 | |
| ToppCell | TCGA-Brain-Primary_Tumor-Low_Grade_Glioma|TCGA-Brain / Sample_Type by Project: Shred V9 | 5.20e-06 | 177 | 63 | 5 | e8ab340b20cd41554c3841fe980e078e878af35f | |
| ToppCell | Primary_Visual_cortex_(V1C)-Neuronal-Inh_GABAergic-i_Gaba_3-GABA_SST|Primary_Visual_cortex_(V1C) / Sample groups (6 Anatomical region groups), with 5 level hierarchy of cell types | 6.80e-06 | 187 | 63 | 5 | 85f1678338a47d91e296f0620d4887f057eb7e70 | |
| ToppCell | -Unknown-Endothelial-Myofibroblast| / V2 postpublication: Rhesus Genome Updated; Treatment groups by lineage, cell_type_level1, cell_type_level2 | 6.97e-06 | 188 | 63 | 5 | 6468fa95ad0395395301115286f2d8c0df5d3882 | |
| ToppCell | -Unknown-Endothelial| / V2 postpublication: Rhesus Genome Updated; Treatment groups by lineage, cell_type_level1, cell_type_level2 | 6.97e-06 | 188 | 63 | 5 | 7a81ac5c79c3eb26639b52d2b9fd5e7ef9798fd6 | |
| ToppCell | -Unknown| / V2 postpublication: Rhesus Genome Updated; Treatment groups by lineage, cell_type_level1, cell_type_level2 | 6.97e-06 | 188 | 63 | 5 | 9cb718bfe1358c6fd842f096e228eb0abb9aefc6 | |
| ToppCell | Neuronal-Inhibitory-iB-iB_4(SST)-B3GAT2|Neuronal / cells hierarchy compared to all cells using T-Statistic | 9.41e-06 | 200 | 63 | 5 | 858421b91f5207b7934b5c219752cb9322a3da31 | |
| ToppCell | Neuronal-Inhibitory-iB-iB_4(SST)-STK32A|Neuronal / cells hierarchy compared to all cells using T-Statistic | 9.41e-06 | 200 | 63 | 5 | 8d51b4f7b7002ee51401ebe5eaca1e8f04bfadd5 | |
| ToppCell | Neuronal-Inhibitory-iB-iB_3(PVALB-SST)|Neuronal / cells hierarchy compared to all cells using T-Statistic | 9.41e-06 | 200 | 63 | 5 | 107854f4855fc99c9f7e737eb246f0d868e6c5fd | |
| ToppCell | Macroglial-Polydendrocytes-PDGFRA---|Macroglial / cells hierarchy compared to all cells using T-Statistic | 9.41e-06 | 200 | 63 | 5 | 4fc3de4bff7ed2bf40b38462c4b4e9b87af6a4ca | |
| ToppCell | Macroglial-Polydendrocytes-PDGFRA-|Macroglial / cells hierarchy compared to all cells using T-Statistic | 9.41e-06 | 200 | 63 | 5 | f17b5a54e8f9eba9dcd0808ba4e8d275ac41bce2 | |
| ToppCell | Macroglial-Polydendrocytes-PDGFRA--|Macroglial / cells hierarchy compared to all cells using T-Statistic | 9.41e-06 | 200 | 63 | 5 | cc3409518f8b436ea92deb955e81114b3f410ff7 | |
| ToppCell | Neuronal-Inhibitory-iB-iB_4(SST)-STK32A-|Neuronal / cells hierarchy compared to all cells using T-Statistic | 9.41e-06 | 200 | 63 | 5 | 6a44439e4a7ce3627271375b04cfcfb9467218f4 | |
| ToppCell | Neuronal-Inhibitory-iB-iB_4(SST)-STK32A--L4-5|Neuronal / cells hierarchy compared to all cells using T-Statistic | 9.41e-06 | 200 | 63 | 5 | cb1f4b0d66da5b0466ff17b29e7034d451d93e4f | |
| ToppCell | Macroglial-Polydendrocytes-PDGFRA----L1-6|Macroglial / cells hierarchy compared to all cells using T-Statistic | 9.41e-06 | 200 | 63 | 5 | 310cd53db1c137f6af74e6ae682221d7ac27310c | |
| ToppCell | Macroglial-Polydendrocytes-PDGFRA|Macroglial / cells hierarchy compared to all cells using T-Statistic | 9.41e-06 | 200 | 63 | 5 | c24a3099e3d96d8b72f6d05286bb355d661a0377 | |
| ToppCell | Neuronal-Inhibitory-iB-iB_4(SST)-B3GAT2-|Neuronal / cells hierarchy compared to all cells using T-Statistic | 9.41e-06 | 200 | 63 | 5 | a7022762c1d8aedb7b3e9605873b1e68b9907b35 | |
| ToppCell | Neuronal-Inhibitory-iB-iB_4(SST)-B3GAT2--L4-6|Neuronal / cells hierarchy compared to all cells using T-Statistic | 9.41e-06 | 200 | 63 | 5 | 2131c8e7fa054b79906eaf60536da892438b09cd | |
| ToppCell | Macroglial-Polydendrocytes|Macroglial / cells hierarchy compared to all cells using T-Statistic | 9.41e-06 | 200 | 63 | 5 | 961858738ce35db8760c8c2e136f8369bc444ccf | |
| ToppCell | facs-Marrow-B-cells-24m-Lymphocytic-precursor_B_cell|Marrow / Spleen_Marrow_Thymus - method, tissue, subtissue, age, lineage, cell ontology and free annotation | 7.79e-05 | 160 | 63 | 4 | c381ec6be8cf887861cc18f831a20db42f953fe1 | |
| ToppCell | facs-Marrow-B-cells-24m-Lymphocytic-pre_B_cell|Marrow / Spleen_Marrow_Thymus - method, tissue, subtissue, age, lineage, cell ontology and free annotation | 7.79e-05 | 160 | 63 | 4 | 25c8f3d2a6d14ff0ca0b965fce89d3ff22f40585 | |
| ToppCell | facs-Heart-LV-3m-Mesenchymal-atrial_myocyte|Heart / Tongue_Heart_Limb_Muscle_Aorta_Diaphragm - method, tissue, subtissue, age, lineage, cell ontology and free annotation | 8.78e-05 | 165 | 63 | 4 | af59a095ecc6758abc13d763c00e44447c488167 | |
| ToppCell | facs-Heart-LV-3m-Mesenchymal-atrial_cardiomyocyte|Heart / Tongue_Heart_Limb_Muscle_Aorta_Diaphragm - method, tissue, subtissue, age, lineage, cell ontology and free annotation | 8.78e-05 | 165 | 63 | 4 | 84eca6a0f5e996b6955ae79fa102af239098fe8f | |
| ToppCell | LV-16._Neuronal|World / Chamber and Cluster_Paper | 8.78e-05 | 165 | 63 | 4 | 6ed52cb756d21addf46c7f6c457458b01339fe04 | |
| ToppCell | facs-Brain_Non-Myeloid-Cerebellum-3m-Epithelial-neuronal_stem_cell|Brain_Non-Myeloid / Brain_Non-Myeloid_Brain_Myeloid - method, tissue, subtissue, age, lineage, cell ontology and free annotation | 8.78e-05 | 165 | 63 | 4 | 1703d3eb644b3c743ad3c5532b1d29ea010c79c8 | |
| ToppCell | LA-16._Neuronal|World / Chamber and Cluster_Paper | 9.41e-05 | 168 | 63 | 4 | 2fd1fd2a16ac1c5eb028f93cc3a2477c7747693e | |
| ToppCell | LA-16._Neuronal|LA / Chamber and Cluster_Paper | 9.41e-05 | 168 | 63 | 4 | c55bbfbde8bb954f1cb9af82007bdd1f8070fee3 | |
| ToppCell | COVID-19_Mild-PLT_2|World / Disease Group and Platelet Clusters | 9.63e-05 | 169 | 63 | 4 | 6abfdc8b437f19c03b408bedc245059d28c6ba6a | |
| ToppCell | LV-16._Neuronal|LV / Chamber and Cluster_Paper | 9.63e-05 | 169 | 63 | 4 | a8fc8ab0f0757e939e213efb61c03cfe390bf7d2 | |
| ToppCell | facs-Diaphragm-Limb_Muscle-24m|Diaphragm / Tongue_Heart_Limb_Muscle_Aorta_Diaphragm - method, tissue, subtissue, age, lineage, cell ontology and free annotation | 9.63e-05 | 169 | 63 | 4 | 12bdc709bc000d7f9061ecd9fbd57233eaacb7e2 | |
| ToppCell | droplet-Lung-nan-21m-Myeloid-dendritic_cell|Lung / Lung_Trachea - method, tissue, subtissue, age, lineage, cell ontology and free annotation | 1.01e-04 | 171 | 63 | 4 | 159ce6d5513008532dd7785b915b3fe7440cc4b2 | |
| ToppCell | TCGA-Brain-Primary_Tumor|TCGA-Brain / Sample_Type by Project: Shred V9 | 1.05e-04 | 173 | 63 | 4 | f6ba22661e67c17d49d1058d4170ba8f36bf47f0 | |
| ToppCell | facs-Diaphragm-Limb_Muscle-24m-Mesenchymal|Diaphragm / Tongue_Heart_Limb_Muscle_Aorta_Diaphragm - method, tissue, subtissue, age, lineage, cell ontology and free annotation | 1.05e-04 | 173 | 63 | 4 | 66f37c1437705734b20601656fa4aa1d92ca30be | |
| ToppCell | facs-Diaphragm-Limb_Muscle-24m-Mesenchymal-nan|Diaphragm / Tongue_Heart_Limb_Muscle_Aorta_Diaphragm - method, tissue, subtissue, age, lineage, cell ontology and free annotation | 1.05e-04 | 173 | 63 | 4 | 649b08a409095592cccf31883be69c754411280d | |
| ToppCell | facs-Diaphragm-Limb_Muscle-24m-Mesenchymal-skeletal_muscle_satellite_cell|Diaphragm / Tongue_Heart_Limb_Muscle_Aorta_Diaphragm - method, tissue, subtissue, age, lineage, cell ontology and free annotation | 1.08e-04 | 174 | 63 | 4 | f230d23618a6487f2664efb2c677e0a4559e2bf4 | |
| ToppCell | facs-Marrow-B-cells-24m|Marrow / Spleen_Marrow_Thymus - method, tissue, subtissue, age, lineage, cell ontology and free annotation | 1.10e-04 | 175 | 63 | 4 | 887e75fc90e59a6394d62f3c048a9cfdf6707725 | |
| ToppCell | PCW_05-06-Neuronal-Neuronal_SCP-neuro_pre_proliferating_SCP_(4)|PCW_05-06 / Celltypes from embryonic and fetal-stage human lung | 1.15e-04 | 177 | 63 | 4 | 59726bfd98f656fdcedf448a7e2e76a9bfad8285 | |
| ToppCell | RA-16._Neuronal|RA / Chamber and Cluster_Paper | 1.23e-04 | 180 | 63 | 4 | 5842febfdabac61ce970254fb0ef17a628f1b8c0 | |
| ToppCell | AT2_cells-Myositis-ILD_01|World / lung cells shred on cell class, cell subclass, sample id | 1.25e-04 | 181 | 63 | 4 | ed0ea67f0607073aedf153f8d1073b35e46127c3 | |
| ToppCell | RA-16._Neuronal|World / Chamber and Cluster_Paper | 1.25e-04 | 181 | 63 | 4 | 7d22a43f887e0747f0cb87ba364ff27905ee6eec | |
| ToppCell | Primary_Motor_Cortex_(M1)-Neuronal-Inh_GABAergic-i_Gaba_3-GABA_PVALB_1-Inh_L5_PVALB_CNTNAP3P2|Primary_Motor_Cortex_(M1) / Sample groups (6 Anatomical region groups), with 5 level hierarchy of cell types | 1.31e-04 | 183 | 63 | 4 | 121791ef84e7ce377ed6f5b7953af8865e04958e | |
| ToppCell | PCW_05-06-Epithelial-Epithelial_alveolar-distal-epi_SOX9^high_Etv5^high_distal_(10)|PCW_05-06 / Celltypes from embryonic and fetal-stage human lung | 1.34e-04 | 184 | 63 | 4 | fa4915b0498f3069fd5ef497286445528f75187e | |
| ToppCell | droplet-Pancreas-Endocrine-18m-Endothelial-nan|Pancreas / Large_Intestine_Pancreas_Liver - method, tissue, subtissue, age, lineage, cell ontology and free annotation | 1.36e-04 | 185 | 63 | 4 | 512a195ebbae445afe3722a3943020080daf2f3c | |
| ToppCell | Mid-temporal_gyrus_(MTG)-Neuronal-Inh_GABAergic-i_Gaba_3-GABA_SST-Inh_L5-6_SST_ISOC1|Mid-temporal_gyrus_(MTG) / Sample groups (6 Anatomical region groups), with 5 level hierarchy of cell types | 1.36e-04 | 185 | 63 | 4 | ae53aa2ecfe418a5dbd7d963a995bc06dab94f56 | |
| ToppCell | Mid-temporal_gyrus_(MTG)-Neuronal-Inh_GABAergic-i_Gaba_3-GABA_PVALB_1-Inh_L5_PVALB_CNTNAP3P2|Mid-temporal_gyrus_(MTG) / Sample groups (6 Anatomical region groups), with 5 level hierarchy of cell types | 1.42e-04 | 187 | 63 | 4 | d413fb4b1531b297af5012a392b88128510c2de8 | |
| ToppCell | primary_auditory_cortex_(A1C)-Neuronal-Inh_GABAergic-i_Gaba_3-GABA_SST-Inh_L2-4_SST_AHR|primary_auditory_cortex_(A1C) / Sample groups (6 Anatomical region groups), with 5 level hierarchy of cell types | 1.42e-04 | 187 | 63 | 4 | 01393f6d1983eb4a2bcc80252012f77892851679 | |
| ToppCell | Somatosensory_Cortex_(S1)-Neuronal-Inh_GABAergic-i_Gaba_1-GABA_L1_LAMP5-Inh_L1_LAMP5_NDNF|Somatosensory_Cortex_(S1) / Sample groups (6 Anatomical region groups), with 5 level hierarchy of cell types | 1.48e-04 | 189 | 63 | 4 | f0aaf2994d319a39877d2845eaab9f166adead4e | |
| ToppCell | Primary_Motor_Cortex_(M1)-Neuronal-Inh_GABAergic-i_Gaba_3|Primary_Motor_Cortex_(M1) / Sample groups (6 Anatomical region groups), with 5 level hierarchy of cell types | 1.51e-04 | 190 | 63 | 4 | d19bc44310c53726e2f5f6a2bd377bbbf1d1983f | |
| ToppCell | Mid-temporal_gyrus_(MTG)-Neuronal-Inh_GABAergic-i_Gaba_3-GABA_SST-Inh_L2-4_SST_AHR|Mid-temporal_gyrus_(MTG) / Sample groups (6 Anatomical region groups), with 5 level hierarchy of cell types | 1.54e-04 | 191 | 63 | 4 | 782bc7946417549ffd39e5b596db659436fa01ba | |
| ToppCell | facs-Lung-Endomucin_-18m|Lung / Lung_Trachea - method, tissue, subtissue, age, lineage, cell ontology and free annotation | 1.57e-04 | 192 | 63 | 4 | ba3fe97786564dba1c8185f2802ce1b57f4f3cc9 | |
| ToppCell | Anterior_Cingulate_gyrus_(CgG)-Neuronal-Inh_GABAergic-i_Gaba_3-GABA_SST|Anterior_Cingulate_gyrus_(CgG) / Sample groups (6 Anatomical region groups), with 5 level hierarchy of cell types | 1.57e-04 | 192 | 63 | 4 | dc40ef2341e5d6a6d479f140e023fe1bf687928d | |
| ToppCell | primary_auditory_cortex_(A1C)-Neuronal-Inh_GABAergic-i_Gaba_3-GABA_PVALB_1-Inh_L5_PVALB_CNTNAP3P2|primary_auditory_cortex_(A1C) / Sample groups (6 Anatomical region groups), with 5 level hierarchy of cell types | 1.57e-04 | 192 | 63 | 4 | 0003d7ef9a8e521e70ac33c63aad843d9b6215c2 | |
| ToppCell | facs-Lung-Endomucin_|Lung / Lung_Trachea - method, tissue, subtissue, age, lineage, cell ontology and free annotation | 1.57e-04 | 192 | 63 | 4 | 85d4d0df701451daf95e94a87a0096da1e86533b | |
| ToppCell | Anterior_Cingulate_gyrus_(CgG)-Neuronal-Inh_GABAergic-i_Gaba_3-GABA_SST-Inh_L3-5_SST_MAFB|Anterior_Cingulate_gyrus_(CgG) / Sample groups (6 Anatomical region groups), with 5 level hierarchy of cell types | 1.60e-04 | 193 | 63 | 4 | c7e9e6e4bf5e07c9cbdf1aa7c8828f4b2500e3ff | |
| ToppCell | Somatosensory_Cortex_(S1)-Neuronal-Inh_GABAergic-i_Gaba_3-GABA_SST|Somatosensory_Cortex_(S1) / Sample groups (6 Anatomical region groups), with 5 level hierarchy of cell types | 1.60e-04 | 193 | 63 | 4 | d1445b8bf2bab36e1a326ddb2a528151db016c7d | |
| ToppCell | Somatosensory_Cortex_(S1)-Neuronal-Inh_GABAergic-i_Gaba_3-GABA_SST-Inh_L4-6_SST_MTHFD2P6|Somatosensory_Cortex_(S1) / Sample groups (6 Anatomical region groups), with 5 level hierarchy of cell types | 1.60e-04 | 193 | 63 | 4 | 8b77625bf3c87d39767fb391d1beaca4ab02342b | |
| ToppCell | Primary_Motor_Cortex_(M1)-Neuronal-Inh_GABAergic-i_Gaba_3-GABA_SST|Primary_Motor_Cortex_(M1) / Sample groups (6 Anatomical region groups), with 5 level hierarchy of cell types | 1.60e-04 | 193 | 63 | 4 | 010717ca052b6c8a525a43aaeffddea0d1113e63 | |
| ToppCell | facs-Lung-Endomucin_-18m-Endothelial-endothelial_cell_of_lung|Lung / Lung_Trachea - method, tissue, subtissue, age, lineage, cell ontology and free annotation | 1.60e-04 | 193 | 63 | 4 | 2218833749576ba1a0fc95bd155c781e7e1163c6 | |
| ToppCell | primary_auditory_cortex_(A1C)-Neuronal-Inh_GABAergic-i_Gaba_3-GABA_SST|primary_auditory_cortex_(A1C) / Sample groups (6 Anatomical region groups), with 5 level hierarchy of cell types | 1.60e-04 | 193 | 63 | 4 | 3ed46f5a7419ec4eddbd0df0d9b5f53aa486198b | |
| ToppCell | TCGA-Prostate-Primary_Tumor-Prostate_Adenocarcinoma-Acinar_Adenocarcinoma-6|TCGA-Prostate / Sample_Type by Project: Shred V9 | 1.60e-04 | 193 | 63 | 4 | abd71b2cf667ef2b1c4d88acd0c1dd19a12ff659 | |
| ToppCell | Mid-temporal_gyrus_(MTG)-Neuronal-Inh_GABAergic-i_Gaba_3-GABA_SST|Mid-temporal_gyrus_(MTG) / Sample groups (6 Anatomical region groups), with 5 level hierarchy of cell types | 1.60e-04 | 193 | 63 | 4 | 2189da4b727e25e62669d7b9257f06493be21a27 | |
| ToppCell | Epithelial-club_cell|World / Lineage, Cell type, age group and donor | 1.60e-04 | 193 | 63 | 4 | 2bdd09004fa433550958ec42ba4b06271a4aaf7c | |
| ToppCell | Somatosensory_Cortex_(S1)-Neuronal-Inh_GABAergic-i_Gaba_3-GABA_SST-Inh_L3-5_SST_MAFB|Somatosensory_Cortex_(S1) / Sample groups (6 Anatomical region groups), with 5 level hierarchy of cell types | 1.60e-04 | 193 | 63 | 4 | e74fdc8718fe0933e1f4dd3fe37e2134983b99b6 | |
| ToppCell | primary_auditory_cortex_(A1C)-Neuronal-Inh_GABAergic-i_Gaba_3-GABA_SST-Inh_L3-5_SST_MAFB|primary_auditory_cortex_(A1C) / Sample groups (6 Anatomical region groups), with 5 level hierarchy of cell types | 1.60e-04 | 193 | 63 | 4 | 658c2b30a4d806c5ce78ea4392fe8eb86b8d1e99 | |
| ToppCell | COVID-19-Endothelial_cells-Inflamed_endothelial_cells|COVID-19 / group, cell type (main and fine annotations) | 1.60e-04 | 193 | 63 | 4 | 979ebefa527f86bebeea5d94e626ee6c1cc7d53b | |
| ToppCell | facs-Lung-Endomucin_-18m-Endothelial|Lung / Lung_Trachea - method, tissue, subtissue, age, lineage, cell ontology and free annotation | 1.64e-04 | 194 | 63 | 4 | df56e23f1dcf1902d29392fcc947e0e268e1648b | |
| ToppCell | LPS-antiTNF-Stromal_mesenchymal|LPS-antiTNF / V2 postpublication: Rhesus Genome Updated; Treatment groups by lineage, cell_type_level1, cell_type_level2 | 1.64e-04 | 194 | 63 | 4 | 6e13549f697f7478b34fe71f7dd9d63c5d3db22e | |
| ToppCell | nucseq-Epithelial-Epithelial_Alveolar-Secretory/RAS-RAS|nucseq / Celltype signatures by Technology, Lineage, Lineage_subclass, Celltype_group, Cell_type2 | 1.64e-04 | 194 | 63 | 4 | a58841b34efe673671a9a059238e044a7254b279 | |
| ToppCell | Primary_Motor_Cortex_(M1)-Neuronal-Inh_GABAergic-i_Gaba_3-GABA_SST-Inh_L3-5_SST_MAFB|Primary_Motor_Cortex_(M1) / Sample groups (6 Anatomical region groups), with 5 level hierarchy of cell types | 1.64e-04 | 194 | 63 | 4 | 1bcb3fafd498614f7bac2b1c9b7de56e39110f65 | |
| ToppCell | nucseq-Epithelial-Epithelial_Alveolar-Secretory/RAS|nucseq / Celltype signatures by Technology, Lineage, Lineage_subclass, Celltype_group, Cell_type2 | 1.64e-04 | 194 | 63 | 4 | 0cd4363627acd419e00d6d32f6dce10430aa6487 | |
| ToppCell | Bronchial-NucSeq-Epithelial-Epi_airway_secretory-Secretory_Club|NucSeq / Cell types per location group and 10X technology with lineage, and cell group designations | 1.70e-04 | 196 | 63 | 4 | ed76eeb37400ca154feae9b7ebaddb6c434f8b81 | |
| ToppCell | Mid-temporal_gyrus_(MTG)-Neuronal|Mid-temporal_gyrus_(MTG) / Sample groups (6 Anatomical region groups), with 5 level hierarchy of cell types | 1.70e-04 | 196 | 63 | 4 | 676c56b44ac29f7baecb62f49bb8597cc74c0a88 | |
| ToppCell | Bronchial-NucSeq-Stromal-Schwann-Schwann_Myelinating|NucSeq / Cell types per location group and 10X technology with lineage, and cell group designations | 1.70e-04 | 196 | 63 | 4 | efeb272bc9e37e60d15d056b7574991c5c7501bc | |
| ToppCell | 5'-Airway_Nasal-Epithelial-Epithelial_transtional-secretory-nasal_mucosa_goblet_cell-Goblet_(nasal)-Goblet_(nasal)_L.0.2.2.0|5' / 5'-vs-3', Tissue groups, Lineages, Lineage subclass, Cell_type2, Cell_subtype2_L4.5 | 1.74e-04 | 197 | 63 | 4 | 5c4cee914baf7cb43e9cb99cc9e3ae823856dc15 | |
| ToppCell | mild-low-quality_cells|mild / Cohort 1 (10x PBMC) with disease condition, cell group and cell class | 1.74e-04 | 197 | 63 | 4 | e4331969bd911d1ebb5453f40a7057297b5389b4 | |
| ToppCell | Somatosensory_Cortex_(S1)-Neuronal|Somatosensory_Cortex_(S1) / Sample groups (6 Anatomical region groups), with 5 level hierarchy of cell types | 1.77e-04 | 198 | 63 | 4 | c01091ef18e096d792ea2a7a715764a5b215355f | |
| ToppCell | primary_auditory_cortex_(A1C)-Neuronal|primary_auditory_cortex_(A1C) / Sample groups (6 Anatomical region groups), with 5 level hierarchy of cell types | 1.77e-04 | 198 | 63 | 4 | 6d18b45eda4014759e6dd282d78ffd28df8a6044 | |
| ToppCell | Primary_Visual_cortex_(V1C)-Neuronal|Primary_Visual_cortex_(V1C) / Sample groups (6 Anatomical region groups), with 5 level hierarchy of cell types | 1.77e-04 | 198 | 63 | 4 | 8ab40fae14fe02e39bc8c8da187a5cd60c787643 | |
| ToppCell | Control_saline-Mesenchymal_fibroblastic-Fibroblasts-Activated_MatrixFB|Control_saline / Treatment groups by lineage, cell group, cell type | 1.77e-04 | 198 | 63 | 4 | 0c4d2c68a42f8a9e964e2dd28092fe75f5216834 | |
| ToppCell | Primary_Motor_Cortex_(M1)-Neuronal|Primary_Motor_Cortex_(M1) / Sample groups (6 Anatomical region groups), with 5 level hierarchy of cell types | 1.77e-04 | 198 | 63 | 4 | 4ca5ff320905ab4ff60ed90a5522227c782142a6 | |
| ToppCell | Neuronal-Inhibitory-iB-iB_4(SST)-ADGRG6-|Neuronal / cells hierarchy compared to all cells using T-Statistic | 1.84e-04 | 200 | 63 | 4 | a9cdddc4e985dae59521e557479c24fcc2ac727d | |
| ToppCell | Neuronal-Inhibitory-iB-iB_3(PVALB-SST)-FRZB|Neuronal / cells hierarchy compared to all cells using T-Statistic | 1.84e-04 | 200 | 63 | 4 | e79d93d55b25804f2608185168da472301b6ebca | |
| ToppCell | Neuronal-Inhibitory-iB-iB_4(SST)|Neuronal / cells hierarchy compared to all cells using T-Statistic | 1.84e-04 | 200 | 63 | 4 | 347a510755374c6a66acee326565dfc447993f18 | |
| ToppCell | Neuronal-Inhibitory-iB-iB_3(PVALB-SST)-NPM1P10--L5-6|Neuronal / cells hierarchy compared to all cells using T-Statistic | 1.84e-04 | 200 | 63 | 4 | 2ea33ac1970791e6a601ac1e407ef32e4833792d | |
| ToppCell | Neuronal-Inhibitory-iB-iB_4(SST)-GXYLT2-|Neuronal / cells hierarchy compared to all cells using T-Statistic | 1.84e-04 | 200 | 63 | 4 | fe63aa1febd2bf650a7dd4e8b4420063580644ba | |
| ToppCell | LPS_anti-TNF-Mesenchymal_myocytic|LPS_anti-TNF / Treatment groups by lineage, cell group, cell type | 1.84e-04 | 200 | 63 | 4 | 67dcbd86fbc79fd585d0793f979e4aac100326c9 | |
| ToppCell | Control_saline-Mesenchymal_myocytic-Myofibroblastic-Myofibroblast|Control_saline / Treatment groups by lineage, cell group, cell type | 1.84e-04 | 200 | 63 | 4 | c5e051f1aac8dda376c342a9932785a23450e073 | |
| ToppCell | LPS_anti-TNF-Endothelial-Endothelial-Activated_Alv_Cap|LPS_anti-TNF / Treatment groups by lineage, cell group, cell type | 1.84e-04 | 200 | 63 | 4 | bcd1cc96197929d6011903803b6f4ccdcf52b4ce | |
| ToppCell | Bronchial-NucSeq-Epithelial-Epi_airway_basal|NucSeq / Cell types per location group and 10X technology with lineage, and cell group designations | 1.84e-04 | 200 | 63 | 4 | 8827653738a931e4a4545e0c7d75be12bed40740 | |
| ToppCell | Neuronal-Inhibitory-iB-iB_4(SST)-KLHDC8A|Neuronal / cells hierarchy compared to all cells using T-Statistic | 1.84e-04 | 200 | 63 | 4 | 05bcde6ce8f1354ef65e4eb9cbd963a92108081c | |
| ToppCell | Control_saline-Mesenchymal_myocytic-Pericyte|Control_saline / Treatment groups by lineage, cell group, cell type | 1.84e-04 | 200 | 63 | 4 | cb7ef774b6d300f8019c5b16a04e3ebd165e4f1c | |
| ToppCell | Neuronal-Inhibitory-iB-iB_4(SST)-ADGRG6--L3-5|Neuronal / cells hierarchy compared to all cells using T-Statistic | 1.84e-04 | 200 | 63 | 4 | 33b9199e0dfc267e2cea20b82d1c167f8adcc635 | |
| ToppCell | LPS_only-Endothelial-Endothelial-Activated_Alv_Cap|LPS_only / Treatment groups by lineage, cell group, cell type | 1.84e-04 | 200 | 63 | 4 | edb64556b3fefe3144f73b6efe23b9ffd34091d2 | |
| ToppCell | Control_saline-Mesenchymal_myocytic-Myofibroblastic|Control_saline / Treatment groups by lineage, cell group, cell type | 1.84e-04 | 200 | 63 | 4 | 9d5b3c2dcfa55d50acc2ce2c319d51aa525d4cd1 | |
| ToppCell | LPS_IL1RA_TNF-Endothelial-Endothelial-Activated_Gen_Cap|LPS_IL1RA_TNF / Treatment groups by lineage, cell group, cell type | 1.84e-04 | 200 | 63 | 4 | 3585484c7e24e941708bee471ca607d8ccee74e6 | |
| ToppCell | Neuronal-Inhibitory-iB-iB_4(SST)-GXYLT2|Neuronal / cells hierarchy compared to all cells using T-Statistic | 1.84e-04 | 200 | 63 | 4 | 37728d83b246dd70933d1f52f938bc1c401df7b9 | |
| ToppCell | Neuronal-Inhibitory-iB-iB_4(SST)-ADGRG6|Neuronal / cells hierarchy compared to all cells using T-Statistic | 1.84e-04 | 200 | 63 | 4 | 9719fabddc34051949468a7520289e3c750de4f8 | |
| Computational | Ion channels. | 1.03e-04 | 70 | 38 | 4 | MODULE_316 | |
| Drug | T0702 | 6.44e-07 | 25 | 63 | 4 | CID000005908 | |
| Drug | Br2BAPTA | 7.01e-07 | 7 | 63 | 3 | CID003081001 | |
| Drug | [[(2R,3S,4R)-5-(2-amino-6-oxo-3H-purin-9-yl)-3,4-dihydroxyoxolan-2-yl]methoxy-hydroxyphosphoryl] [(2R,3S,4R,5R)-3,4,5-trihydroxyoxolan-2-yl]methyl hydrogen phosphate | 7.01e-07 | 7 | 63 | 3 | CID009547999 | |
| Drug | LY339434 | 1.68e-06 | 9 | 63 | 3 | CID006324635 | |
| Drug | R 478 | 3.28e-06 | 11 | 63 | 3 | CID000084223 | |
| Drug | 8-amino-cADPR | 3.28e-06 | 11 | 63 | 3 | CID003081323 | |
| Drug | mag-fura-2 | 3.28e-06 | 37 | 63 | 4 | CID000123839 | |
| Drug | XeC compound | 3.60e-06 | 84 | 63 | 5 | CID000005701 | |
| Drug | hexachlorophene | 5.06e-06 | 90 | 63 | 5 | CID000003598 | |
| Drug | gamma-aminobutyric acid | 5.95e-06 | 474 | 63 | 9 | CID000000119 | |
| Drug | 5-nitro-6,7,8,9-tetrahydrobenzo(G)indole-2,3-dione-3-oxime | 7.54e-06 | 2 | 63 | 2 | ctd:C084273 | |
| Drug | indo-1 | 8.08e-06 | 99 | 63 | 5 | CID000105060 | |
| Drug | riluzole | 8.66e-06 | 174 | 63 | 6 | CID000005070 | |
| Drug | Gvapspat amide | 8.97e-06 | 15 | 63 | 3 | CID000125015 | |
| Drug | decahydroisoquinoline | 1.10e-05 | 16 | 63 | 3 | CID000097812 | |
| Drug | AC1L1FA8 | 1.11e-05 | 50 | 63 | 4 | CID000003150 | |
| Drug | NSC7524 | 1.12e-05 | 182 | 63 | 6 | CID000005657 | |
| Drug | lamotrigine | 1.75e-05 | 116 | 63 | 5 | CID000003878 | |
| Drug | AC1NBU2S | 1.82e-05 | 117 | 63 | 5 | CID004473765 | |
| Drug | AC1L380G | 1.90e-05 | 19 | 63 | 3 | CID000084698 | |
| Drug | LY382884 | 1.90e-05 | 19 | 63 | 3 | CID000656723 | |
| Drug | kynurenic acid | 2.23e-05 | 122 | 63 | 5 | CID000003845 | |
| Drug | fluo-3 | 2.23e-05 | 122 | 63 | 5 | CID000104978 | |
| Drug | Valproic Acid | 2.26e-05 | 3 | 63 | 2 | DB00313 | |
| Drug | 2-hydroxycarbazole | 2.26e-05 | 3 | 63 | 2 | CID000093551 | |
| Drug | cis-diammineplatinum(II | 2.26e-05 | 3 | 63 | 2 | CID000159790 | |
| Drug | 2-hydroxyheptanoic acid | 2.26e-05 | 3 | 63 | 2 | CID002750949 | |
| Drug | Ryanodyl 3-(pyridine-3-carboxylate | 2.26e-05 | 3 | 63 | 2 | CID005748312 | |
| Drug | 8N3-cADPR | 2.26e-05 | 3 | 63 | 2 | CID000127713 | |
| Drug | aminodantrolene | 2.26e-05 | 3 | 63 | 2 | CID009570289 | |
| Drug | caffeine | 2.31e-05 | 562 | 63 | 9 | CID000002519 | |
| Drug | lactobionic acid | 2.59e-05 | 21 | 63 | 3 | CID000007314 | |
| Drug | NS 102 | 2.99e-05 | 22 | 63 | 3 | CID005282252 | |
| Drug | pioglitazone | 3.22e-05 | 326 | 63 | 7 | CID000004829 | |
| Drug | gallopamil | 3.58e-05 | 67 | 63 | 4 | CID000001234 | |
| Drug | L-Glutamic Acid | 3.80e-05 | 68 | 63 | 4 | DB00142 | |
| Drug | AC1L2AC7 | 4.02e-05 | 69 | 63 | 4 | CID000068733 | |
| Drug | felbamate | 4.26e-05 | 70 | 63 | 4 | CID000003331 | |
| Drug | aminothiazole 6 | 4.51e-05 | 4 | 63 | 2 | CID005329388 | |
| Drug | PCB74 | 4.51e-05 | 4 | 63 | 2 | CID000036218 | |
| Drug | 148504-47-6 | 4.51e-05 | 4 | 63 | 2 | CID006444275 | |
| Drug | acromelic acid B | 4.51e-05 | 4 | 63 | 2 | CID000158974 | |
| Drug | SC 38249 | 4.51e-05 | 4 | 63 | 2 | CID000134834 | |
| Drug | Brn 1074551 | 4.51e-05 | 4 | 63 | 2 | CID000120220 | |
| Drug | AC1L1U7A | 4.51e-05 | 4 | 63 | 2 | CID000035682 | |
| Drug | diCl-HQC | 4.51e-05 | 4 | 63 | 2 | CID003018579 | |
| Drug | ethosuximide | 5.30e-05 | 74 | 63 | 4 | CID000003291 | |
| Drug | bromowillardiine | 7.50e-05 | 5 | 63 | 2 | CID000167842 | |
| Drug | ipenoxazone | 7.50e-05 | 5 | 63 | 2 | CID000065882 | |
| Drug | pBB-PzDA | 7.50e-05 | 5 | 63 | 2 | CID000124528 | |
| Drug | 3-hydroxy-2-quinoxalinecarboxylic acid | 7.50e-05 | 5 | 63 | 2 | CID000071001 | |
| Drug | ferrocenium hexafluorophosphate | 7.50e-05 | 5 | 63 | 2 | CID011727263 | |
| Drug | pyrimidine-2,4-dione | 7.50e-05 | 5 | 63 | 2 | CID000150747 | |
| Drug | cis-2,3-piperidine dicarboxylic acid | 7.77e-05 | 30 | 63 | 3 | CID000001226 | |
| Drug | LY293558 | 7.77e-05 | 30 | 63 | 3 | CID000127894 | |
| Drug | 4-methylglutamic acid | 8.59e-05 | 31 | 63 | 3 | CID000005365 | |
| Drug | willardine | 9.46e-05 | 32 | 63 | 3 | CID000005123 | |
| Drug | cobalt-60 | 9.94e-05 | 390 | 63 | 7 | CID000061492 | |
| Drug | CNS 1145 | 1.04e-04 | 33 | 63 | 3 | CID000190902 | |
| Drug | IHC-64 | 1.04e-04 | 33 | 63 | 3 | CID000162753 | |
| Drug | gabapentin | 1.05e-04 | 169 | 63 | 5 | CID000003446 | |
| Drug | 3-acetylisoquinoline | 1.12e-04 | 6 | 63 | 2 | CID000124656 | |
| Drug | MBED | 1.12e-04 | 6 | 63 | 2 | CID000129958 | |
| Drug | chloro-m-cresol | 1.12e-04 | 6 | 63 | 2 | CID000012008 | |
| Drug | AC1O528X | 1.12e-04 | 6 | 63 | 2 | CID006475857 | |
| Drug | NSC114784 | 1.12e-04 | 6 | 63 | 2 | CID000419425 | |
| Drug | R,S)-AMPA | 1.35e-04 | 36 | 63 | 3 | CID000001221 | |
| Drug | 5-iodouracil | 1.35e-04 | 36 | 63 | 3 | CID000069672 | |
| Drug | 1,2-dichlorohexafluorocyclobutane | 1.47e-04 | 37 | 63 | 3 | CID000009643 | |
| Drug | gamma-Glu-Gly | 1.47e-04 | 37 | 63 | 3 | CID000100099 | |
| Drug | acrylyl-coenzyme A | 1.47e-04 | 37 | 63 | 3 | CID000439340 | |
| Drug | 4-chloro-m-cresol | 1.47e-04 | 37 | 63 | 3 | CID000001732 | |
| Drug | Azumoleno | 1.57e-04 | 7 | 63 | 2 | CID000056259 | |
| Drug | dec-5-ene | 1.57e-04 | 7 | 63 | 2 | CID000023916 | |
| Drug | mag-indo-1 | 1.57e-04 | 7 | 63 | 2 | CID000131881 | |
| Drug | fluorocyclobutane | 1.57e-04 | 7 | 63 | 2 | CID011051569 | |
| Drug | nitroxide | 1.57e-04 | 7 | 63 | 2 | CID005460582 | |
| Drug | nitrendipine | 1.58e-04 | 98 | 63 | 4 | CID000004507 | |
| Drug | GAMs | 1.59e-04 | 38 | 63 | 3 | CID000002935 | |
| Drug | L-BMAA | 1.59e-04 | 38 | 63 | 3 | CID000028558 | |
| Drug | AC1L98DX | 1.59e-04 | 38 | 63 | 3 | CID000439957 | |
| Drug | DETC-MeSO | 1.72e-04 | 39 | 63 | 3 | CID003035711 | |
| Drug | NAADP | 1.72e-04 | 39 | 63 | 3 | CID000123952 | |
| Drug | AC1L1DXE | 1.77e-04 | 299 | 63 | 6 | CID000002548 | |
| Drug | baclofen | 1.87e-04 | 191 | 63 | 5 | CID000002284 | |
| Drug | AC1L96VB | 1.87e-04 | 191 | 63 | 5 | CID000439200 | |
| Drug | Kainic Acid | 2.01e-04 | 194 | 63 | 5 | ctd:D007608 | |
| Drug | Etofenamate [30544-47-9]; Down 200; 10.8uM; MCF7; HT_HG-U133A | 2.06e-04 | 195 | 63 | 5 | 7327_DN | |
| Drug | 8-bromoguanosine 3',5'-cyclic monophosphate | 2.08e-04 | 308 | 63 | 6 | CID000001915 | |
| Drug | 9 mM of H | 2.09e-04 | 8 | 63 | 2 | CID000130464 | |
| Drug | AC1L1B65 | 2.09e-04 | 8 | 63 | 2 | CID000001300 | |
| Drug | perzinfotel | 2.09e-04 | 8 | 63 | 2 | CID006918236 | |
| Drug | Protriptyline hydrochloride [1225-55-4]; Up 200; 13.4uM; PC3; HT_HG-U133A | 2.11e-04 | 196 | 63 | 5 | 6338_UP | |
| Drug | Procyclidine hydrochloride [1508-76-5]; Up 200; 12.4uM; HL60; HT_HG-U133A | 2.16e-04 | 197 | 63 | 5 | 2991_UP | |
| Drug | Bicuculline (+) [485-49-4]; Up 200; 10.8uM; MCF7; HT_HG-U133A | 2.16e-04 | 197 | 63 | 5 | 4397_UP | |
| Drug | Chlorpheniramine maleate [113-92-8]; Down 200; 10.2uM; MCF7; HT_HG-U133A | 2.21e-04 | 198 | 63 | 5 | 2217_DN | |
| Drug | Pyrilamine maleate [59-33-6]; Down 200; 10uM; PC3; HT_HG-U133A | 2.21e-04 | 198 | 63 | 5 | 5869_DN | |
| Drug | Isoniazid [54-85-3]; Down 200; 29.2uM; PC3; HT_HG-U133A | 2.26e-04 | 199 | 63 | 5 | 2083_DN | |
| Drug | Joro spider toxin | 2.30e-04 | 43 | 63 | 3 | CID000119582 | |
| Drug | escina | 2.47e-04 | 44 | 63 | 3 | CID006433489 | |
| Disease | congenital myopathy 1A (implicated_via_orthology) | 1.18e-05 | 3 | 59 | 2 | DOID:3529 (implicated_via_orthology) | |
| Disease | malignant hyperthermia (implicated_via_orthology) | 1.18e-05 | 3 | 59 | 2 | DOID:8545 (implicated_via_orthology) | |
| Disease | amino acid measurement | 5.88e-05 | 678 | 59 | 8 | EFO_0005134 | |
| Disease | oral microbiome measurement | 8.25e-05 | 42 | 59 | 3 | EFO_0801229 | |
| Disease | Drug habituation | 8.45e-05 | 115 | 59 | 4 | C0013170 | |
| Disease | Substance-Related Disorders | 8.45e-05 | 115 | 59 | 4 | C0236969 | |
| Disease | Drug abuse | 8.45e-05 | 115 | 59 | 4 | C0013146 | |
| Disease | Drug Use Disorders | 8.45e-05 | 115 | 59 | 4 | C0013222 | |
| Disease | Drug Dependence | 8.45e-05 | 115 | 59 | 4 | C1510472 | |
| Disease | Substance Dependence | 8.45e-05 | 115 | 59 | 4 | C0038580 | |
| Disease | Substance Use Disorders | 8.45e-05 | 115 | 59 | 4 | C0038586 | |
| Disease | Organic Mental Disorders, Substance-Induced | 8.45e-05 | 115 | 59 | 4 | C0029231 | |
| Disease | Prescription Drug Abuse | 8.45e-05 | 115 | 59 | 4 | C4316881 | |
| Disease | Substance abuse problem | 8.73e-05 | 116 | 59 | 4 | C0740858 | |
| Disease | Autistic Disorder | 1.77e-04 | 261 | 59 | 5 | C0004352 | |
| Disease | smoking cessation | 4.84e-04 | 325 | 59 | 5 | EFO_0004319 | |
| Disease | pulmonary hypertension (biomarker_via_orthology) | 5.59e-04 | 80 | 59 | 3 | DOID:6432 (biomarker_via_orthology) | |
| Disease | serum IgG glycosylation measurement | 6.13e-04 | 523 | 59 | 6 | EFO_0005193 | |
| Disease | colorectal health | 7.10e-04 | 201 | 59 | 4 | EFO_0008460 | |
| Disease | status epilepticus (implicated_via_orthology) | 8.05e-04 | 21 | 59 | 2 | DOID:1824 (implicated_via_orthology) | |
| Disease | phosphatidylserines measurement | 9.68e-04 | 23 | 59 | 2 | EFO_0020049 | |
| Disease | Huntington's disease (is_implicated_in) | 9.68e-04 | 23 | 59 | 2 | DOID:12858 (is_implicated_in) | |
| Disease | Sensorineural Hearing Loss (disorder) | 9.68e-04 | 23 | 59 | 2 | C0018784 | |
| Disease | attention deficit hyperactivity disorder, unipolar depression, bipolar disorder, autism spectrum disorder, schizophrenia | 1.10e-03 | 101 | 59 | 3 | EFO_0003756, EFO_0003761, EFO_0003888, MONDO_0004985, MONDO_0005090 |
| Peptide | Gene | Start | Entry |
|---|---|---|---|
| KTFMEMNGKLFDELT | 426 | Q15173 | |
| GKKSKDMSTERDFFM | 156 | Q99814 | |
| MKSMSTFIEEAYKKL | 251 | Q7L2Z9 | |
| DFILMKKMGIKSGFT | 31 | Q7Z407 | |
| KIMPASTFDMDKLKS | 146 | Q8N4J0 | |
| SSLFMIMLGDKEKTF | 1071 | Q96NH3 | |
| DVRKSKGSMFSQAMK | 606 | O43572 | |
| MTFFKKSKISTYEKM | 706 | P39086 | |
| SLFKSSKPFKVMMTA | 236 | Q49SQ1 | |
| TFTDEEMMIKSSVKK | 56 | P45954 | |
| SSKHDKMFSLSSMKF | 1476 | Q8WZ64 | |
| FGDFLTVMTQKMSEK | 86 | P41208 | |
| MEEDSFFMESMSFKK | 256 | Q8WWL7 | |
| MMSDKKSERFFKVLH | 1776 | Q14573 | |
| AFSKMNGSMDKKSST | 186 | Q8IWT6 | |
| FEKMMSGSDIKSTDK | 636 | Q8NCI6 | |
| MGSEKVTEMYQFKFK | 111 | Q8N7B1 | |
| GFHSMKVKVMTEATK | 226 | Q8N7B1 | |
| KKSIIGMMEFSLFGI | 2431 | O43451 | |
| DVMTFSKKMMTGGFF | 351 | P80404 | |
| ATNMKMFTSKLKEGS | 3161 | Q5CZC0 | |
| SAVKMKMFGKLTRDT | 596 | Q9BRR8 | |
| KLFMRMASKFMGKTD | 616 | Q2TBE0 | |
| TFTMSLLGTKEKMQK | 371 | P11150 | |
| MTTDDFVKMFSGKLK | 371 | Q6YN16 | |
| KKFMETTMNKKGDFL | 381 | Q6ZN66 | |
| EKMGKKLKCMFSSFF | 411 | O60774 | |
| FFSDMSKHMIFKQKI | 756 | P98164 | |
| KKDKDFSSMRTNIGM | 146 | Q9NZH7 | |
| TFMQKGTKFDIKRMV | 341 | P49917 | |
| AFTSKLEGMFKDMEL | 486 | Q13619 | |
| FKKGAEMFSKRMDSF | 211 | Q8NEU8 | |
| MKISSMGELTSKEFE | 701 | Q0VDD8 | |
| KFGELVMTKESKALM | 326 | P40939 | |
| CAMFTGDMSESKAKK | 76 | Q9UH77 | |
| MTFFKKSKISTYDKM | 691 | Q13002 | |
| AVKDGATMTFFKKSK | 686 | Q13003 | |
| VKKMTVKDMVTAFFS | 4271 | Q92736 | |
| FTSKLEGMFKDMELS | 641 | Q13620 | |
| KSFPFVKMFITKMIS | 41 | A6NMZ7 | |
| KFFDNKTGKMIHSMV | 706 | Q13033 | |
| EGKEMFATMSKLKEQ | 781 | Q8NF91 | |
| PDKTMMDGSFSFKLL | 346 | Q6XZB0 | |
| KTFTMSVSEMKSSGK | 296 | A6NI28 | |
| MKKKGRAFFGTMDTL | 61 | Q8TBE7 | |
| ITSYSKDASSEKMMK | 586 | Q5T5P2 | |
| EMFMKEFKELTSKNS | 306 | Q86YF9 | |
| KFSDTSKAFMDIMSA | 186 | Q5JTH9 | |
| KSKMKAHTMTDDVTF | 96 | Q00610 | |
| QSFFTKMAKKKSLMD | 246 | P48736 | |
| RMGFSFKDIKKIMEE | 381 | P98170 | |
| FLTGDSKSKMSKAMQ | 3326 | Q15413 | |
| KEFSMMFKHFDKDKS | 2326 | Q13813 | |
| MEMASKMKDTGFIVF | 186 | Q0D2K0 | |
| TMKELEFSKDKILMG | 566 | Q96TA2 | |
| GYESMASKEDFKSMK | 436 | Q8N9V7 | |
| ASKEDFKSMKSFIGK | 441 | Q8N9V7 | |
| FEKQMGSHEMFSKKE | 131 | Q9BX82 | |
| KMMKFLKTGGETASR | 566 | Q9H892 | |
| FATFKQEMDKTTKKM | 381 | Q8N3L3 | |
| LMSFTKNLGKFEDDM | 191 | P48553 | |
| AAKMLSFTEEEFMKA | 371 | Q8N6V9 | |
| MDFSLFKEVFESSKM | 856 | Q9NYU2 | |
| EVFTTFKQEMEKMTK | 406 | P40222 | |
| MSKTFVKSKEMGELV | 1 | Q9HD90 |